Piero Vernia

Cattedra di Gastroenterologia 1, Dipartimento di Scienze Cliniche, Policlinico Umberto I, Università di Roma "La Sapienza", Italy

Piero Vernia, MD

Academic positions:
- Associate Professor, Gastroenterology

All industry positions (in last five years):
None declared

Research interests:
Inflammatory bowel diseases, short chain fatty acids, lactase deficiency and lactose intolerance.

Any other information:
Dr Vernia is a member of the Società Italiana di Gastroentrologia (SIGE), IG-IBD and American Gastroentrological Association (AGA).

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Gastroenterology & Hepatology > Colon & Rectum (since 15 November 2005)

All recent recommendations

• 3.0
  Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients.
  Recommended by Piero Vernia
  
• 3.0
  Assessment of the extension and the inflammatory activity in Crohn's disease: comparison of ultrasound and MRI.
  Recommended by Piero Vernia
  
• 3.4
  Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.
  Recommended by Jon Markowitz, Eduard Stange, Piero Vernia, William Berquist with Anita Talisetti
  
• 3.0
  Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study.
  Recommended by Piero Vernia
  
• 3.0
  Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients.
  Recommended by Piero Vernia
  
• 3.0
  Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease.
  Recommended by Piero Vernia
  
• 3.0
  Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
  Recommended by Piero Vernia
  
• 3.0
  Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study.
  Recommended by Piero Vernia
  
• 3.0
  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.
  Recommended by Piero Vernia
  
• 3.0
  Perianal fistulas in Crohn's disease are predominantly colonized by skin flora: implications for antibiotic treatment?
  Recommended by Piero Vernia